IceCure Medical Ltd.

Good morning, and thank you for standing by. Currently, all of the participants are in listen-only mode. After management discussion, there will be a question-and-answer session. Please be advised that today's conference call is being recorded. I would now like to turn the conference over to Michael Polyview. Please go ahead.

Thank you, Operator, and welcome to IceCure Medical's conference call to review the financial results as of and for the three months ended March 31, 2026. and provide an update on recent operational highlights. You may refer to the earnings press release that we issued earlier this morning. Participating on today's call are Ice Care Medical's CEO, Al Shamir, the company's VP of sales, North America, Shad Good, and our guest, Dr. Richard Fine, a key opinion leader in the treatment of breast cancer, a breast surgeon, and Ice III investigator who has published and presented Ice III data and is active in hands-on trainings and symposia for Cryoablation and the Treatment of Early-Stage Breast Cancer. Before we begin, I will now take a moment to read a statement about overlooking statements. This call and the question and answer section that follows it contains overlooking statements within the meaning of the SAPAR provisions of the Private Securities Litigation and Reform Act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, and estimates And similar expressions or variations of such words are intended to identify pro-local statements. For example, we're using pro-local statements in this presentation when we discussed ISEER's accelerating commercial momentum and growing engagement for ProSense, recurring revenue potential, converting growing interest into system sales and installations. The expectation to report continued growth in active accounts during the second quarter of 2026. planned expansion of the U.S. commercial team and sales footprint and plans regarding CPT reimbursement codes. The forward-looking statements contained or implied during this call are subject to other risks and uncertainties, many of which are beyond control of the company, including those set forth in the risk factor section of the company's annual report on Form 20F, the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 17, 2026. which is available on the SEC's website at www.sec.gov. The company exclaims any intention or obligation, except as required by law, to update or revise any prologue statements, whether because of new information, future events, or otherwise. This conference contains time-sensitive information and speaks only as of the live broadcast today, May 12, 2026. I will now turn the call over to Ice Gear Medical's CEO, Al Shamir, Please go ahead.

Thank you, Michael, and thank you all for joining us today. As you saw in our press release issued earlier this morning, we are off to a very strong and encouraging start to 2026. We reported revenue growth of 26% year over year for the first quarter, with particularly strong performance in North America, where sales increased by 84%, and the U.S. where the cells grow by 31%, reflecting both increased system cells and growing utilization of disposable probes. In the interest of time, and since Shad and Dr. Fine will provide additional insight, I encourage you to review our press release for full financial details. Our results clearly demonstrate high skills accelerating commercial momentum, particularly in the U.S., following FDA clearance for low-risk early breast cancer, the continued conversion of our growing pipeline in your active customers, and the expanding clinical and scientific validation supporting process. During the first quarter, we experienced meaningful progress across several key areas of our business from a revenue standpoint Growth was driven by a new system placement and increasing sales of disposable props, which reflects rising portfolio volume at both new and existing customer sites. There is growing engagement across a range of customer types, including the most prestigious large hospital network in the world, regional hospitals network, and especially in outpatient clinics. Many of those customers are integrating process into their existing workflow, which continues to be a key advantage of our system, and it does not require additional infrastructure or complex integration. We are also encouraged by increasing procedural activities and an important indicator for long-term adoption and recurring revenue potential. Turning to our U.S. commercial progress, the momentum we discussed last quarter is translating into a measurable growth. Prior to FDA approval, we had 13 active accounts, including some with multiple system installation. Since FDA approval, we added several new accounts and reactivated others that have been inactive while waiting FDA clearance. As a result, we increased our active account space to 19, representing 46 increase compared to active accounts prior to the FDA approval. We are encouraged by this level of growth and based on currently available information, we expect to report continued growth in active accounts during the second quarter. This expansion reflects new customer acquisition and growing confidence among existing institutions, many of which represents large healthcare networks where we see meaningful opportunities for additional system placement within our current customer's network. While the U.S. remains our primary focus, it is important to note that the FDA clearance has also a meaningful global impact. We are seeing increased interest across Europe, Asia, and the Americas. This is particularly event at international medical conferences where a growing number of physicians and researchers are expressing interest in adopting process and initiating new studies using process for breast cancer. For example, while process has had CE mark approval in Europe for breast cancer for some times, the FDA clearance has had a visible impact on increased interest. This growing global engagement is consistent with our expectation and for the role of FDA clearance as a key validation for our technology. I will now turn a call over to Shad who will provide more details on our U.S. commercial activities and pipeline.